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1ABSTRACT
ABSTRACT 
Acute coronary syndromes (ACS) represent an important public health problem. The adult human 
heart possesses a detectable, but limited endogenous regenerative capacity, which has attracted 
much interest and lead to intensive research during the past years. Endothelial progenitor stem 
cells (EPCs) are multipotent adult stem cells, originated from the bone marrow, that are mobilized 
to the peripheral circulation in response to many stimuli. EPCs play a pivotal role in postnatal 
neovascularization, being essential for vascular repair of the ischemic myocardium. Levels of 
circulating EPCs significantly increase in response to an acute myocardial infarction (AMI), high-
lighting the importance of EPCs-mediated repair as a “survival” response of the organism to severe 
ischemia. Additionally, it has been demonstrated that EPCs mobilization may also be induced by 
pharmacological intervention. Several drugs, including statins and many antidiabetic agents have 
been found to increase circulating EPCs levels and/or improve their function. Type 2 diabetes 
mellitus (DM) significantly worsens outcome following an ACS. Therefore, the pharmacological 
modulation of endogenous EPCs response to facilitate vasculogenesis in ischemic tissues is of 
utmost interest in this growing population. However, it is well recognized that both numbers and 
function of EPCs are impaired in DM, reflecting a poor endogenous regenerative capacity. This 
raises the question of whether pharmacological therapies based on the stimulation of endogenous 
EPCs are still effective in diabetic patients.
The overall goal of the present translational research was to study the potential of pharmacologi-
cal stimulation of endogenous EPCs in patients with AMI, focusing on the impact of statins and 
insulin therapy on EPCs levels and function in diabetic patients. The specific aims were: first, to 
quantitatively and functionally study the EPCs response of diabetic patients to an AMI; second, to 
evaluate the impact of prior chronic statin therapy in circulating EPCs levels in the acute phase of 
the myocardial infarction (MI) and of high-intensity statin therapy at discharge on the evolution 
of circulating EPCs following the AMI; third, to evaluate the effects of statins on EPCs function 
and to assess the impact of chronic antidiabetic treatment in EPCs response to an AMI in diabetic 
patients.
This project was divided in two phases: 1) an in vivo phase, to characterize and quantify circu-
lating EPCs in AMI patients and 2) an in vitro phase, to functionally evaluate the EPCs. In the 
first phase of this research, 100 AMI patients were prospectively included and their circulating 
EPCs (CD45dimCD34+KDR+, CD45dimCD133+KDR+ cells and their subpopulations co-expressing 
the homing marker CXCR-4) were quantified by flow cytometry (FACS), in two different moments: 
within the first 24 hours of admission and 3 months post-AMI. Patients were followed-up for 2 
years. In the second phase of this research, circulating EPCs were obtained from 10 diabetic and 
10 age-matched non-diabetic male patients with ST segment elevation AMI (STEMI). For each 
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patient, cultures of early and late EPCs were performed under four different conditions: 1) normal 
glucose concentration (control); 2) high glucose concentration; 3) normal glucose concentration 
with atorvastatin supplementation and 4) normal glucose concentration with pravastatin supple-
mentation. The functional assays performed were: EPC colony-forming units (CFU); cell cycle 
analysis; viability assessment and expression of the surface markers CXCR4, CD133, CD34 and KDR.
The FACS analysis showed significant lower levels of circulating CD45dimCD34+KDR+ and 
CD45dimCD133+KDR+ EPCs in diabetic by comparison with non-diabetic AMI patients, with a par-
allel decrease in the subpopulations CXCR4+ (p<0.001). Indeed, the impaired response of EPCs to 
an AMI was present even in pre-diabetes and numbers of all EPCs populations were inversely cor-
related with glycosylated hemoglobin (r=-0.432, p<0.001 for CD45dimCD34+KDR+ EPCs). Previous 
chronic insulin therapy seemed to attenuate the impaired response of diabetic EPCs to the AMI. 
On the other hand, chronic statin pre-treatment strongly increased circulating EPCs levels in 
acute MI phase, even in diabetic patients. Additionally, high-intensity statin therapy at discharge 
prevented the expected decrease of circulating EPCs levels during follow-up. The in vitro study 
showed that despite the profound functional impairment of EPCs from diabetic AMI patients, they 
are still responsive to statin stimulation.
In conclusion, DM dramatically impairs the response of endogenous EPCs to an AMI, by affecting 
their numbers and function. This EPCs impairment is already present in pre-diabetic patients. 
Finally, the degree of glycemic control seems to be determinant for circulating EPCs levels and 
pharmacological stimulation of the endogenous EPCs seems to be a realistic goal in the treatment 
of AMI, even in diabetic patients. 
Key words: endothelial progenitor cells, diabetes mellitus, pre-diabetes, acute myocardial infarc-
tion, statins, insulin
3RESUMO
RESUMO
As Síndromes Coronárias Agudas (SCA) constituem um importante problema de saúde pública. O 
coração humano adulto possui uma capacidade regenerativa endógena detectável, mas limitada, 
que  tem despertado muito interesse e conduzido a intensa investigação durante os últimos anos. 
As células progenitoras endoteliais (EPCs) são células estaminais adultas multipotentes, com 
origem na medula óssea, que são mobilizadas para a circulação periférica em resposta a vários 
estímulos. As EPCs desempenham um papel crucial na neovascularização pós-natal, sendo essen-
ciais para a reparação vascular do miocárdio isquémico. Os níveis de EPCs circulantes aumentam 
significativamente em resposta a um enfarte agudo do miocárdio (EAM), salientando a importân-
cia da reparação mediada por EPCs como resposta “fisiológica” do organismo à isquemia grave. 
Adicionalmente, tem sido demonstrado que a mobilização das EPCs também pode ser induzida por 
intervenção farmacológica. Vários fármacos, incluindo estatinas e vários antidiabéticos mostraram 
aumentar os níveis de EPCs circulantes e/ou melhorar a sua função. A diabetes mellitus tipo 2 
(DM) agrava significativamente o prognóstico após uma SCA. Portanto, a modulação farmacológica 
da resposta endógena das EPCs para facilitar a vasculogénese nos tecidos isquémicos é do máximo 
interesse nesta população crescente. No entanto, a desregulação numérica e funcional das EPCs 
associada à DM é bem reconhecida e traduz-se numa pobre capacidade regenerativa endógena. 
Isto leva-nos a questionar se o tratamento farmacológico baseado na estimulação de EPCs endó-
genas será eficaz mesmo em doentes diabéticos.  
O objectivo global da presente investigação translacional foi estudar o potencial efeito da estimu-
lação farmacológica das EPCs endógenas em doentes com EAM, focando no impacto das estatinas 
e da insulinoterapia nos níveis e função das EPCs de doentes diabéticos. Os objectivos específicos 
foram: em primeiro lugar, estudar quantitativa e funcionalmente a resposta das EPCs de doentes 
diabéticos a um EAM; em segundo lugar, avaliar o impacto do tratamento crónico prévio com es-
tatinas nos níveis de EPCs circulantes na fase aguda do enfarte do miocárdio (EM) e do tratamento 
com estatina de intensidade elevada na alta hospitalar na evolução das EPCs circulantes após o 
EAM;  em terceiro lugar, avaliar os efeitos das estatinas na função das EPCs e o impacto do trata-
mento antidiabético crónico na resposta das EPCs a um EAM, em doentes diabéticos. 
Este projeto foi dividido em duas fases: 1) uma fase in vivo, para caracterização e quantificação 
das EPCs circulantes em doentes com EAM e 2) uma fase in vitro para avaliação funcional das 
EPCs.  Na primeira fase desta investigação, foram incluídos prospectivamente 100 doentes com 
EAM e as suas EPCs circulantes (células CD45dimCD34+KDR+, CD45dimCD133+KDR+ e as suas sub-
populações co-expressando o marcador de homing CXCR-4) foram quantificadas por citometria de 
fluxo (FACS), em dois momentos distintos: nas primeiras 24 horas da admissão e 3 meses após o 
EAM. Os doentes foram seguidos durante 2 anos. Na segunda fase desta investigação, obtivemos 
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EPCs circulantes de 10 doentes diabéticos e 10 não diabéticos, emparelhados por idade, todos do 
sexo masculino, com EAM com elevação do segmento ST (EAMCST). Para cada doente, realizamos 
culturas celulares de “early” e “late” EPCs em quatro condições distintas: 1) concentração de 
glicose normal (controlo); 2) elevada concentração de glicose; 3) concentração de glicose normal 
na presença de atorvastatina e 4) concentração de glicose normal na presença de pravastatina. 
Os testes funcionais realizados foram:  unidades formadoras de colónias de EPCs (CFU); análise 
do ciclo celular; avaliação da viabilidade e expressão dos marcadores de superfície CXCR4, CD133, 
CD34 e KDR.
Na análise de FACS, os doentes diabéticos apresentaram níveis de EPCs CD45dimCD34+KDR+ e 
CD45dimCD133+KDR+ significativamente menores que os doentes não diabéticos com EAM, com 
redução paralela nas subpopulações CXCR4+ (p<0,001). Adicionalmente, observou-se desregula-
ção da resposta das EPCs ao EAM mesmo nos doentes com pré-diabetes e os números de todas 
as populações de EPCs apresentaram uma relação inversamente proporcional com a hemoglobina 
glicosilada (r=-0,432, p<0,001 para as EPCs CD45dimCD34+KDR+). A insulinoterapia crónica prévia 
aparentou atenuar a desregulação da resposta das EPCs diabéticas a um EAM.  Por outro lado, o 
pré-tratamento crónico com estatinas aumentou significativamente os níveis de EPCs circulantes 
na fase aguda do EM, mesmo nos doentes diabéticos. Complementarmente, o tratamento com es-
tatina de intensidade elevada na alta hospitalar, preveniu a redução nos níveis de EPCs circulantes 
que seria expectável durante o período de seguimento clínico. O estudo in vitro mostrou  que 
apesar do profundo distúrbio funcional das EPCs dos doentes diabéticos com EAM, estas células 
ainda apresentam capacidade de resposta à estimulação das estatinas.
Em conclusão, a DM prejudica drasticamente a resposta endógena das EPCs a um EAM, afectando 
quer os seus níveis quer a sua função. Este distúrbio das EPCs está presente mesmo nos doentes 
com pré-diabetes. Finalmente, o grau de controlo glicémico  parece ser determinante para os 
níveis de EPCs circulantes e a estimulação farmacológica das EPCs endógenas parece ser um ob-
jectivo realista no tratamento do EAM, mesmo em doentes diabéticos. 
Palavras-chave: células progenitoras endoteliais, diabetes mellitus, pré-diabetes, estatinas, 
insulina
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THESIS OUTLINE
This thesis is divided in four parts, whose content is summarized below.
Part I is a general introduction to the thesis, giving an overview of the state of the art in post-
natal neovascularization mediated by endothelial progenitor cells, in the clinical setting of acute 
myocardial infarction and diabetes mellitus, with special emphasis on the potential pharmacologi-
cal modulation of their endogenous response.
In Part II, we summarize the key research aims that will be addressed in this thesis.
Part III of this thesis contains the papers published in international peer-reviewed journals, in-
cluding two systematic reviews (Chapters I and II) and three original articles (Chapters III to V). 
Chapter I, Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascu-
lar drugs, comprises the review article that constitutes the genesis of all original research that 
brought light to this thesis. 
In Chapter II, Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients, the 
most relevant mechanisms underlying dysfunction of endothelial progenitor cells in diabetes are 
reviewed. 
Chapter III and IV include two original papers concerning the results of the in vivo study of en-
dothelial progenitor cells in patients with acute myocardial infarction. Chapter III, comprises the 
manuscript Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction 
patients with diabetes or pre-diabetes: accompanying the glycemic continuum and Chapter IV the 
manuscript Impact of prior chronic statin therapy and high intensity statin therapy at discharge on 
circulating endothelial progenitor cells levels in patients with acute myocardial infarction: a prospec-
tive observational study.
Chapter V comprises an original paper that addresses the in vitro part of this research, concern-
ing the functional study of endothelial progenitor cells, Endothelial Progenitor Cells of Diabetic 
Patients with Myocardial Infarction – Can Statins Improve their Function?.
Part IV includes an integrated conclusion summarising the main results of this thesis and, since 
research gives answers but always raises even more questions, an outlook on potential lines of 
future research will be presented.
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INTRODUCTION
INTRODUCTION
Acute coronary syndromes (ACS) represent a major global public health concern. Despite the 
considerable progress achieved in their pharmacological and interventional treatment over the 
past decade, they remain a source of high morbidity and mortality worldwide[1, 2]. As a result, 
ACS still require continued research to improve treatment options and outcome. 
The adult human heart possesses a detectable but limited endogenous regenerative capacity, 
which makes regenerative intervention an attractive treatment for myocardial infarction (MI)[3, 
4]. Endothelial progenitor cells (EPCs) play a pivotal role in postnatal neovascularization, being 
essential for vascular repair of the ischemic myocardium[5-7].  Importantly, there is an intensi-
fication of EPCs mobilization from bone marrow and a markedly increase in circulating EPCs after 
ACS, highlighting the importance of EPCs-mediated tissue and vessel repair as a “physiological” 
response of the organism to severe ischemia[8, 9]. Additionally, there is a strong body of evidence 
showing that EPCs mobilization may be induced, not only by natural stimuli such as myocardial 
ischemia, but also by pharmacological agents. Several drugs, including statins[10-15], blockers of 
the renin-angiotensin-aldosterone system[16, 17], many antidiabetics[18-21], estrogens[22] and 
erythropoietin[23] have been found to increase circulating EPCs levels and/or improve their func-
tion in humans. Statins or 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
have a variety of pleiotropic effects with vasculoprotective and cardioprotective activity and are 
among the most effective drugs to stimulate EPCs[12, 13, 15]. Hence, pharmacological stimula-
tion of endogenous EPCs seems to be a promising strategy in the treatment of ACS patients and 
may bypass the need for the complexities of exogenous cell-based therapy. 
Diabetes mellitus (DM) is a major independent risk factor for coronary artery disease (CAD)[24]. 
Furthermore, diabetic patients have a significantly worse outcome after an ACS than their non-
diabetic counterparts[25-28].  Therefore, the pharmacological modulation of endogenous EPCs 
to facilitate vasculogenesis in ischemic tissues, in an attempt to improve outcome, is of utmost 
interest in this growing population. However, it is well recognized that diabetic patients present 
reduced numbers and dysfunctional circulating EPCs, reflecting a poor endogenous regenerative 
capacity. This raises important questions on the value of pharmacological therapies based on the 
stimulation of endogenous EPCs in diabetic patients: are EPCs from diabetic patients responsive to 
pharmacological modulation? Are pharmacological drugs able to completely correct their dysfunc-
tion or do they simply increase the number of dysfunctional EPCs?
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1. Acute coronary syndromes and myocardial regeneration
Worldwide, CAD is the single most frequent cause of death[32]. The clinical presentations of 
CAD include silent ischemia, ACS, heart failure and sudden death[33]. It is well established that 
ACS in their different clinical presentations (ST-segment elevation myocardial infarction (STEMI), 
non-STEMI, and unstable angina) share a common pathophysiological substrate, that consists of 
rupture or erosion of a vulnerable coronary atherosclerotic plaque, with differing degrees of su-
perimposed thrombosis and distal embolization, resulting in myocardial underperfusion[33, 34]. 
If the ischemic condition persists for a prolonged period of time, irreversible myocardial injury 
and cell death occur[35].  
It was long believed that the human heart was a post-mitotic organ without any intrinsic regen-
erative capacity, and therefore, lost cardiomyocytes resulting from MI or normal aging process 
could not be replaced by newly formed cells[4, 36]. However, in the last decade robust evidence 
demonstrating myocardial regeneration have refuted this dogma.  The study of Quaini et al., 
examining the chimerism of sex-mismatched transplanted heart, presented early evidence for 
myocardial regeneration by demonstrating active renewal of all three germ cell lineages in human 
hearts. This study reported that Y-chromosome-positive cardiomyocytes, vascular smooth muscle 
cells, and endothelial cells were identified in hearts from female donors that were transplanted 
into male recipients, providing direct evidence that these male primitive cells migrated from the 
recipient to the grafted heart[37]. Furthermore, Anversa’s group has demonstrated that the human 
adult heart is capable of replacing its entire population of cardiomyocytes, endothelial cells and 
fibroblasts several times during normal life span and under physiological conditions[4, 38]. 
In summary, the human heart is a highly dynamic organ that retains a significant degree of 
intrinsic regenerative potential throughout life. However, this regenerative capacity is limited 
and insufficient to prevent the negative effects of myocardial infarction. Therefore, cell-based 
regenerative therapy and approaches for potentiating the naturally-occurring process of cardiac 
repair have attracted much attention during the past years, generating new hopes that cardiac 
regeneration might become a realistic therapeutic option for MI.
2. EPCs and postnatal neovascularization
By definition, stem cells are clonogenic cells capable of both self-renewal and differentiation 
into more mature cells. Classically, stem cells are divided in two broad categories: 1) pluripotent 
embryonic stem cells, which are derived from the inner mass of the developing embryo during the 
blastocyst stage, and have the potential to differentiate into any cell type of the adult body and 
2) multipotent adult stem cells, which are more lineage-committed, having therefore the capacity 
to differentiate only into cells of a given germ layer under the appropriate stimuli[39]. EPCs are 
multipotent adult stem cells originated from the bone marrow that can be found circulating in the 
peripheral blood at very low levels under physiological conditions[40]. 
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In a developing embryo, blood vessels are initially formed by a process known as vasculogenesis 
that consists in the development of new vessels from the spontaneous differentiation of bone 
marrow-derived mesodermal stem cells into haemangioblasts, the common precursor of haema-
topoietic stem cells and endothelial-lineage angioblasts[41, 42]. These immature endothelial-
commited angioblasts migrate and congregate into clusters, forming the primitive vascular plexus 
from which a complex microcirculation arises[43]. As the embryo grows, expansion of this vascular 
network depends on angiogenesis, which refers to neovessel formation by in situ proliferation and 
migration of pre-existing resident mature endothelial cells[44-46]. 
In adults, new blood vessel formation (neovascularization) is essential for the maintenance and 
repair of the cardiovascular system. Historically, postnatal neovascularization was thought to oc-
cur exclusively through the mechanism of angiogenesis. However, the discovery of EPCs in 1997 
by Asahara and colleagues changed this paradigm by showing that these multipotent stem cells 
isolated from the peripheral circulation are also capable of forming new blood vessels, even in the 
absence of pre-existing blood vessels (vasculogenesis)[47]. Since then, several studies have shown 
that these bone marrow-derived cells play a pivotal role in human vascular homeostasis and repair, 
by homing to sites of neovascularization and differentiating into mature endothelial cells[5-7, 48]. 
Circulating EPCs in the peripheral blood provide a maintenance reservoir of endothelial cells, and 
contribute up to 25% of endothelial cells in newly formed vessels of ischemic lesions[6, 49, 50].
The recruitment of EPCs from bone marrow to peripheral circulation and then homing to ischemic 
sites is a complex process regulated by many factors, including chemokines and growth factors, 
such as vascular endothelial growth factor (VEGF), granulocyte-colony stimulating factor (G-CSF) 
and stroma-derived factor-1 (SDF-1)[51]. Acute myocardial infarction (AMI) releases local tissue 
VEGF, which in turn initiates the vasculogenic cascade by activating EPCs from their quiescent 
state in the bone marrow, followed by their mobilization into circulation[8, 52-55]. The mobilized 
EPCs then travel (via a process called EPC recruitment or homing) to the sites of needed neovascu-
larization in the ischemic tissue[6]. SDF-1α expression is also increased in heart tissue following 
AMI, representing the most important chemokine to initiate EPCs migration and promote their 
homing to the ischemic areas[55, 56]. SDF-1α mediates its effects through its specific receptor, 
CXCR-4 (C-X-C chemokine receptor type 4)[55, 56]. Hence, the SDF-1/CXCR-4 axis plays a key 
role in the response of EPCs to myocardial ischemia. There is evidence from clinical studies that 
circulating EPCs increase immediately after the onset of an AMI, with a subsequent peak at day 
5 and a rapid decline thereafter, normalizing to baseline levels within 2 months[8, 57, 58]. This 
increase in circulating EPCs levels in the very early phases of an AMI confirms that myocardial 
ischemia is a strong stimulus for endogenous EPCs mobilization. Once at the site of tissue repair, 
EPCs may exert their protective effect over the ischemic myocardium via two main mechanisms: 
1) by a direct action, through the differentiation in mature endothelial cells in situ and physical 
incorporation into new blood vessels[6, 7, 50]; or 2) indirectly through a paracrine action. There 
is ample evidence supporting the hypothesis that paracrine mechanisms mediated by the secre-
tion of a broad range of cytoprotective chemokines, cytokines, and growth factors by EPCs play an 
essential role in vascular repair following an AMI[59-62]. A non-exhaustive list of factors known 
to be released by EPCs includes VEGF, hepatocyte growth factor (HGF), endothelial nitric oxide 
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synthase (eNOS), inducible nitric oxide synthase (iNOS), SDF-1α, and insulin-like growth factor-1 
(IGF-1)[63, 64]. It is important to point out that the paracrine action might include two distinct 
phenomena: the first is the humoral stimulation of endogenous regeneration, and the second is 
the preservation of pre-existing cells. In fact, the soluble factors secreted by EPCs might activate 
stem cells already present in the ischemic tissue (resident stem cells), enhance EPCs proliferation, 
and recruit additional EPCs to the injury sites (mainly via SDF-1α, VEGF, HGF and NOS actions) 
and simultaneously inhibit cell death (mainly via the production of IGF-1, a potent anti-apoptotic 
factor)[59, 65, 66]. Of relevance, irrespective of the mechanisms involved, the final result is a 
protective effect on the cardiovascular system with improved blood supply to the ischemic pen-
umbra, which in turn would augment oxygen supply, and help rescue cells from critical ischemia 
with a resulting decrease in the infarction area[47, 67, 68]. 
3. Phenotypical characterization of EPCs 
The exact definition and phenotypic characterization of EPCs is still an ongoing and unresolved 
question. In general, two approaches have been used to isolate circulating EPCs: a) culture and 
colony assays and b) identification of EPCs based on surface markers by fluorescence-activated 
cell sorting (FACS) or flow cytometry. 
Unfortunately, there is no unique or specific marker that definitely identifies EPCs. By definition, 
EPCs must co-express surface markers of both endothelial cells and progenitor cells, being, there-
fore, possible to identify and quantify circulating EPCs trough the combination of various surface 
markers by flow cytometry[47, 69, 70]. However, given the change in cell membrane marker 
profiles during the process of mobilization and maturation, definition of EPCs by surface antigens 
is extremely challenging[71]. 
When analyzing EPCs by flow cytometry, a method considered the gold standard for the quanti-
fication of these cells in peripheral blood, the minimal antigenic profile should include at least 
one marker for stemness/immaturity (usually CD34 and/or CD133), plus at least one marker for 
endothelial commitment (usually kinase insert domain receptor - KDR, also known as vascular 
endothelial growth factor 2 - VEGFR-2)[71-73]. It is well established that EPCs have a dynamic 
phenotype over time, expressing different patterns of cell surface antigens, throughout their early 
and late stages of maturation. CD133, a surface marker of more immature hematopoietic cells than 
CD34, has been used to define a very early subset of putative EPCs with recognized pro-angiogenic 
activity[49, 74, 75]. 
In order to increase the specificity for EPCs, other surface markers and combinations of several 
antigens have been used by several groups. The parallel analysis of CD45, which is generally 
considered a specific pan-leukocyte marker, seems to be mandatory to distinguish between EPCs 
and myeloid cells (which are CD45+ and may mimic endothelial morphology in culture) [76]. While 
the original putative EPCs were first described as CD45− cells, recent use of polychromatic flow 
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cytometers, with more channels of resolution, has revealed that the EPCs described as CD45− are 
in fact CD45dim[77]. Moreover, it has been demonstrated that only the fraction of CD45dim cells 
harbours the “true” circulating EPCs with high neovascularization capacity[71]. Additionally, the 
SDF-1 receptor CXCR-4, which is required for EPCs homing, has also been used by some investiga-
tors to identify EPCs with a high migration and improved neovascularization capacity[78, 79]. 
This superior functional activity of EPCs coexpressing CXCR-4 seems to be mainly attributed to the 
enhanced homing and the release of multiple pro-angiogenic cytokines[72]. 
The widespread interlaboratory variations in FACS methodology used to identify circulating 
EPCs is still a problem, making interlaboratory comparability and reproducibility a difficult task. 
However, to try to overcome interlaboratory discrepancies, recently, Schmidt-Lucke et al. proposed 
a standardized protocol for identification and quantification of circulating EPCs, adapted from the 
International Society of Hematotherapy and Graft Engineering (ISHAGE) protocol. This standard-
ized protocol seems to have a high accuracy in detecting “true” EPCs, with neovascularization 
potential and is now commonly used to identify circulating EPCs[71].
Regarding culture assays, a strong body of evidence convincingly demonstrates that when periph-
eral blood mononuclear cells are studied in vitro, two different types of EPCs become apparent, 
differing mainly in their time-dependent appearance: 1) early EPCs (also known as circulating 
angiogenic cells or pro-angiogenic cells) and 2) late EPCs (also referred as late outgrowth endo-
thelial cells or endothelial colony-forming cells). Both subsets of EPCs participate in neovascular-
ization, although through different mechanisms. Early EPCs form colonies within 5–7 days and are 
similar to that reported in the landmark study of Ashara et al[47]. These early EPCs have myeloid/
hematopoietic characteristics and share features with immune cells, particularly monocytes/mac-
rophages. They are positive for the endothelial (KDR), hematopoietic (CD45) and immaturity/
stemness (CD133) markers and are also characterized by the ability to uptake acetylated-LDL and 
to bind ulex lectin[80, 81]. However, early EPCs do not incorporate into newly forming blood 
vessels but instead, seem to promote angiogenesis through paracrine mechanisms[75, 82-84]. 
In contrast, late EPCs appear in culture within 7 to 21 days, are positive for CD34 and KDR but 
negative for the endothelial precursor marker CD133 and the leukocyte marker CD45. These EPCs 
obtained from long-term cultures have robust proliferative potential and vessel-forming ability 
in vivo, but have lower cytokine release and therefore, no significant paracrine angiogenic ef-
fects[75, 82, 85, 86]. 
These different methods used to identify and evaluate circulating EPCs seem to have little correla-
tion and might actually complement each other. In fact, the combination of these methods for the 
study of EPCs enables simultaneous quantification of circulating EPCs levels (by flow cytometry) 
and evaluation of the functional capacity of EPCs (trough culture assays), providing complemen-
tary information to the understanding of EPCs biology. 
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4. EPCs biology and type 2 diabetes mellitus
Type 2 DM has already reached epidemic proportions in developed countries, becoming one of 
the leading causes of death and the majority of these deaths are associated with cardiovascular 
diseases [87, 88]. Furthermore, following MI, diabetic patients present a significantly worse prog-
nosis compared with non-diabetic equivalents[25, 26]. 
DM is a metabolic condition that strongly affects EPCs. There is solid evidence that both numbers 
and function of EPCs are impaired in diabetic patients[29-31, 89]. Tepper et al. have convincingly 
demonstrated that EPCs isolated from type 2 diabetic patients displayed reduced proliferation, adhe-
sion and incorporation into tubular structures in vitro[29]. Additionally, it has been experimentally 
shown that high glucose hampers proliferation and survival of EPCs isolated from healthy donors[90, 
91]. However, despite the evidence of dysfunctional EPCs in DM, it remains unclear whether this 
critical dysfunction is mediated by chronic hyperglycemia or is inherent to type 2 DM per se.
The mechanisms underlying circulating EPC levels reduction in diabetes are still poorly understood. 
As the number of circulating EPCs is closely dependent on the balance between mobilization from 
the bone marrow and survival in the peripheral circulation, a defective mobilization could explain 
the reduced circulating levels of EPCs in diabetic patients. An alternative explanation for the 
reduced EPCs counts could be a shortening in peripheral EPCs survival. 
Fadini et al. have shown an impaired EPCs mobilization and a defective compensatory angio-
genesis after ischaemia-reperfusion injury in animal models of diabetes[92]. However, there are 
only a few studies in the literature addressing the dynamics of circulating EPCs numbers in the 
clinical setting of AMI[8, 9]. Despite the logical expectation of poorer bone marrow mobilization 
and lower levels of circulating EPCs in diabetic patients with AMI, when compared with their 
non-diabetic counterparts, data regarding circulating EPCs in diabetic patients with AMI are even 
scarcer[57, 58]. 
Of relevance, reduced EPCs levels have been proposed as a surrogate marker for vascular dysfunc-
tion, which independently predicts cardiovascular events in patients with cardiovascular disease 
[93, 94]. In the clinical setting of AMI, reduced circulating levels of EPCs and impaired migratory 
activity have also been associated with poorer clinical cardiovascular outcomes[95]. Furthermore, 
the reduction in circulating EPCs levels has been associated with the pathogenesis of vascular 
complications in diabetes[30]. 
Both the decreased number of circulating EPCs and their impaired function are likely to have a 
negative impact on vascular integrity and regenerative potential and might, therefore contribute 
to the adverse outcomes of diabetic patients. The quantitative study of the EPCs pool and the 
evaluation of the relative levels of different subsets of EPCs (according to their maturation stage) 
in diabetic patients with AMI, is of major interest. This information could contribute to a better 
understanding of the response of diabetic patients to myocardial ischemia and to a clarification 
of the underlying mechanisms. 
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In the natural history of DM, pre-diabetes appears as an intermediate stage between normal 
glucose metabolism (NGM) and overt DM and it is also associated with increased risk of cardiovas-
cular events[96, 97]. However, there is a lack of studies investigating circulating EPCs in patients 
with pre-diabetes and therefore, their response to an AMI remains unknown. 
5. EPCs as a target for pharmacological stimulation 
Despite some controversy regarding the definition of EPCs, the literature is remarkably consistent 
in attributing to EPCs a critical role in endothelial maintenance and repair[5-7, 47, 55, 98]. 
However, as EPCs are found in limited numbers in the peripheral circulation, the native response 
is often insufficient to ensure an adequate neovascularization without additional intervention. 
Therefore, ways to enhance the regenerative response of EPCs are intuitively appealing and have 
attracted great interest over the past decade. The goal of improving EPCs to facilitate neovas-
cularization in cardiovascular disease can be reached, either by cardiac cell-based regenerative 
therapies or through the stimulation of the endogenous pool of circulating EPCs. Although the 
concept of exogenous stem cell-based therapy for myocardial ischemia is straightforward in theory, 
it is extraordinarily complex and has been hampered by several important practical limitations. In 
fact, cardiac cell-based therapy remains challenged by inconsistent and, overall, modest efficacy, 
disappointingly poor cell engraftment to the therapeutic target zone and long-term safety con-
cerns[99]. Hence, further pre-clinical research is clearly warranted before clinical use of cell-based 
regenerative therapies can be considered.
The stimulation of the endogenous EPCs response appears, therefore as an attractive alternative 
therapeutic strategy for myocardial infarction that may overcome the limitations of exogenous 
cardiac cell-based therapies.
Over the past decade several drugs have been shown to be effective in either enhancing peripheral 
EPCs levels or improving EPCs function[10-13, 15-21, 23]. Particularly, statins exhibit convincing 
beneficial effects on EPCs through multiple mechanisms, including enhancement of proliferation 
and differentiation[10-12], stimulation of EPCs mobilization from the bone-marrow[10, 13], im-
provement of migratory capacity[10, 13, 15], anti-apoptotic effects[12], and increased of EPCs 
homing[14]. 
Statins are potent inhibitors of cholesterol biosynthesis with unequivocal benefits in second-
ary prevention after AMI[100]. Therefore, current guidelines recommend intensive statin therapy 
early after admission in all AMI patients, without contraindication or history of intolerance, 
regardless of initial cholesterol levels[32]. The favorable effects of statins extend beyond their 
cholesterol lowering effects, to include so-called pleiotropic effects. These cholesterol-indepen-
dent effects include, among others, antioxidant and anti-inflammatory actions, atherosclerotic 
plaque-stabilizing properties, anticoagulant activity, decreased platelet aggregation, inhibition 
of cardiac hypertrophy, increased nitric oxide bioavailability, improvement of endothelial function 
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and stimulation of EPCs[10-13, 101]. Since mevalonic acid, the product of HMG-CoA reductase 
reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, 
a suggested mechanism for these pleiotropic effects is the inhibition of isoprenoid synthesis by 
HMG-CoA reductase inhibitors, which leads to the inhibition of important intracellular signaling 
molecules such as Rho, Ras and Rab[101]. 
The beneficial effects of short-term statin therapy on EPCs biology have been demonstrated in patients 
with stable coronary artery disease[10, 71]. However, there are few and controversial clinical data con-
cerning the long-term effects of treatment with statins on these EPCs. In fact, paradoxically, Hristov et 
al have verified that the administration of statins for more then 4 weeks significantly reduced circulat-
ing EPC levels in CAD patients[102]. One the other hand, despite the fact that it is expectable that 
statins also improve the EPCs response to an AMI, unfortunately, to date, no studies have evaluated the 
impact of previous long-term statin therapy on EPCs in AMI patients. Likewise, dose-dependent effects 
of a continuous statin therapy on EPCs in AMI patients have not yet been analyzed.
It is tempting to speculate that the mechanisms underlying the positive effects of statins on 
EPCs are also operative in patients with DM. However, due to the profound impairment of the 
endogenous EPCs pool in diabetic patients, and since no studies examining the direct effects of 
statins on human EPCs have yet been performed, it is important to consider the possibility that 
diabetic EPCs might be refractory to pharmacological stimulation.
Cumulative evidence indicates that levels of circulating EPCs are closely related to the glycemic 
control of diabetic patients, represented by hemoglobin A1C (HbA1c) levels, thus suggesting that 
hyperglycemia is a key factor in the development of EPCs impairment[103-105]. Therefore, it can 
be hypothesized that tight glycemic control, in general and specifically during AMI, might lead 
to a better response of EPCs to myocardial ischemia. Nevertheless, it has been suggested that 
hyperglycemia induces phenotypic changes in cells and vascular dysfunction that persist after 
normalization of glucose levels[106]. This phenomenon has been called “hyperglycemic memory” 
or “metabolic memory” and the hypothesis that it might also produce persistent EPCs dysfunction 
despite an intensive glycemic control has not been ruled out. In this regard, Loomans et al. re-
ported that dysfunction of EPCs from type 1 diabetic patients were maintained, despite culturing 
these EPCs under normoglycemic conditions[107]. The concept of hyperglycemic memory (and 
the ability to reverse it) may, therefore, be an important factor in determining the success of 
pharmacological interventions directed towards improving EPCs in diabetic patients.
Many oral antidiabetic drugs (OAD) and insulin therapy have demonstrated significant EPC-
stimulating effects. Previous clinical studies have shown that metformin (alone or in combina-
tion with glicazide)[108], peroxisome proliferator-activated receptor-γ (PPARγ) agonists, such as 
rosiglitazone and pioglitazone[20, 21, 109, 110] and the dipeptidyl peptidase (DPP)-4 inhibitor, 
sitagliptin[18], increase EPCs levels and improve their function in diabetic patients. Regarding 
insulin therapy, previous in vitro and animal studies have demonstrated a protective role on EPCs 
function. In addition, more recently Marfella et al have shown that EPCs levels increased after 
insulin infusion for intensive glycemic control in AMI patients with hyperglycemia[111]. 
23
INTRODUCTION
Besides the key effect of insulin on the metabolic control of diabetic patients, insulin also seems 
to improve endothelial function[112]. Several mechanisms have been proposed to explain the 
beneficial effect of insulin on endothelial function: reduction of free fatty acids, decrease of oxi-
dative stress and enhancement of nitric oxide production. These mechanisms may also justify the 
protective role of insulin therapy on EPCs biology.  However, insulin may also positively impact on 
EPCs by improving glucose control and removal of the adverse hyperglycemic milieu.
Despite the obvious interest in knowing the impact of chronic antidiabetic therapy on EPCs 
response to an AMI in diabetic patients, to date no studies have explored this issue. Therefore, 
it remains unclear whether antidiabetic drugs and good glycemic control of diabetic patients can 
completely restore chronically reduced and dysfunctional EPCs, translating into a normal neovas-
cularization potential in response to an AMI.
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Endogenous EPCs form part of the body’s defense against vascular damage and ischemic injury. 
However, as the native response of EPCs is insufficient to restore vascular homeostasis after 
an AMI, pharmacological stimulation of the endogenous pool of EPCs represents a promising 
therapeutic strategy to improve vascular repair of the ischemic myocardium. This is especially 
important for patients with AMI and DM, who might have reduced numbers and dysfunctional 
circulating EPCs.
The overall goal of this thesis was to study the potential of pharmacological modulation of the 
endogenous EPCs response to an AMI, focusing on the impact of statins and insulin therapy on 
EPCs levels and function in diabetic patients.
Therefore, the present research was divided in two phases: 1) in vivo quantitative study of the pool 
of circulating EPCs by flow cytometry, and 2) in vitro cell cultures for the simultaneous functional 
evaluation of early and late EPCs obtained from peripheral blood of AMI patients.
In the first phase of this research the specific aims were:
1. To compare the native EPCs response to an AMI between diabetics, pre-diabetics and patients 
with normal glucose metabolism, by quantifying circulating EPCs levels in the early phase of 
the AMI; 
2. To evaluate the impact of glycemic control and the effect of chronic insulin therapy on circu-
lating EPCs levels, in the acute phase of a MI;
3. To assess the impact of prior chronic statin therapy on EPCs response to an AMI; 
4. To analyze the influence of the intensity of statin therapy at discharge on the evolution of 
circulating EPCs levels following the AMI.
In the second phase of this research, the specific aims were:
1. To functionally compare EPCs derived from diabetic with those from non-diabetic patients with 
AMI (cell cultures under control conditions);
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2. To study the effect of hyperglycemia per se on EPCs function, by comparing EPCs derived from 
non-diabetic patients, in culture conditions mimicking clinical hyperglycemia, to those of 
equivalent diabetic patients when removed from the hyperglycemic milieu (cell cultures under 
normal glucose concentration);
3. To evaluate the ability of atorvastatin and pravastatin to reverse the deleterious effects of 
diabetes on EPCs function.
37
PART III
PUBLICATIONS
39
PUBLICATIONS — CHAPTER I
CHAPTER I
Stimulation of endothelial progenitor cells: 
a new putative effect of several 
cardiovascular drugs
Eur J Clin Pharmacol. 2010; 66(3):219-30
53
PUBLICATIONS — CHAPTER II
CHAPTER II
Challenges in vascular repair by endothelial 
progenitor cells in diabetic patients
Cardiovasc Hematol Disord Drug Targets. 2010;10(3):161-6
61
PUBLICATIONS — CHAPTER III
CHAPTER III
Reduced levels of circulating endothelial progenitor cells 
in acute myocardial infarction patients with diabetes or 
pre-diabetes: accompanying the glycemic continuum
Cardiovasc Diabetol. 2014;13:101
63
PUBLICATIONS — CHAPTER III
ORIGINAL INVESTIGATION Open Access
Reduced levels of circulating endothelial
progenitor cells in acute myocardial infarction
patients with diabetes or pre-diabetes:
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Abstract
Background: Diabetic patients have a significantly worse prognosis after an acute myocardial infarction (AMI) than
their counterparts. Previous studies have shown that the number of circulating endothelial progenitor cells (EPCs)
significantly increase early after an AMI in normoglycemic patients. However, it is well known that type 2 diabetes
mellitus (DM) is associated with impaired function and reduced circulating EPCs levels. Nonetheless, few studies
have analyzed EPCs response of diabetics to an AMI and the EPC response of pre-diabetic patients has not been
reported yet. Therefore, we hypothesized that in the acute phase of an AMI, diabetic and pre-diabetics have lower
circulating EPCs levels than patients with normal glucose metabolism. We also evaluated the possible capacity of
chronic antidiabetic treatment in the recovery of EPCs response to an AMI in diabetics.
Methods: One-hundred AMI patients were prospectively enrolled in the study. Using the high-performance flow
cytometer FACSCanto II, circulating EPCs (CD45dimCD34+KDR+ and CD45dimCD133+KDR+ cells) were quantified,
within the first 24 hours of admission. In addition, as an indirect functional parameter, we also analyzed the fraction
of EPCs coexpressing the homing marker CXCR4.
Results: We found that in the acute phase of an AMI, diabetic patients presented significantly lower levels of
circulating CD45dimCD34+KDR+ and CD45dimCD133+KDR+ EPCs by comparison with nondiabetics, with a parallel
decrease in the subpopulations CXCR4+ (p < 0.001). Indeed, this study suggests that the impaired response of EPCs
to an AMI is an early event in the natural history of DM, being present even in pre-diabetes. Our results, also
demonstrated that numbers of all EPCs populations were inversely correlated with HbA1c (r = −0.432, p < 0.001
for CD45dimCD34+KDR+ cells). Finally, this study suggests that previous chronic insulin therapy (but not oral
antidiabetic drugs) attenuate the deficient response of diabetic EPCs to an AMI.
Conclusion: This study indicates that there is a progressive decrease in EPCs levels, from pre-diabetes to DM, in
AMI patients. Moreover, glycemic control seems to be determinant for circulating EPCs levels presented in the acute
phase of an AMI and chronic insulin therapy may probably attenuate the deficit in EPCs pool seen in diabetics.
Keywords: Endothelial progenitor cells, Diabetes, Pre-diabetes, Insulin, Oral antidiabetic drugs, Acute myocardial
infarction, Homing
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Background
It is well recognized that patients with type 2 diabetes mel-
litus (DM) have accelerated atherosclerosis, increased risk
of developing coronary artery disease (CAD) and worse
prognosis after an acute myocardial infarction (AMI) [1].
Endothelial progenitor cells (EPCs), a subpopulation of
adult stem cells, have emerged as critical to endothelial
repair and vascular homeostasis. Although the mecha-
nisms whereby EPCs protect the cardiovascular system
are still not fully understood, it has been extensively
demonstrated that these bone marrow-derived cells
contribute to endothelial repair and postnatal neovascu-
larization [2,3]. EPCs can differentiate into mature endo-
thelial cells and be incorporated into new vessels or act
by a paracrine manner, through the secretion of pro-
angiogenic growth factors that enhance vascularization
mediated by resident endothelial cells and/or promote
angiogenesis [2-5].
The number of EPCs in peripheral circulation is gener-
ally low, and in normal physiological conditions, these
endothelial precursor cells are very rare in blood, but
they are mobilized from the bone marrow to the periph-
eral circulation in response to tissue injury, such as
myocardial ischemia [6]. In fact, tissue ischemia is con-
sidered the strongest stimulus for EPCs mobilization
and it has been shown that their numbers significantly
increase in patients with an AMI [7,8]. However, it is
well established that diabetic patients present impaired
function and reduced numbers of circulating EPCs,
reflecting a poor endogenous regenerative capacity that
may contribute to the development of vascular compli-
cations and to the dismal prognosis associated with this
prevalent disease [9-12]. Therefore, it is likely that, in
the clinical context of myocardial infarction, diabetic pa-
tients also have lower levels of circulating EPCs, but
regrettably the data addressing the dynamics of EPCs
mobilization in diabetic patients with AMI are scarce.
Furthermore, little is known about potential EPCs im-
pairment in pre-diabetic states and no studies are avail-
able on the kinetics of EPCs mobilization in pre-diabetic
patients with AMI. This is of great importance, since
multiple studies have demonstrated that individuals with
pre-diabetes are also at increased risk for cardiovascular
events [13]. On the other hand, some drugs commonly
prescribed in diabetic patients, like statins, angiotensin
II receptor blockers (ARBs) and angiotensin-converting-
enzyme (ACE)-inhibitors, have been shown to increase
the number of EPCs in peripheral blood of patients with
stable CAD [14]. However, we have no data available re-
garding the impact of previous antidiabetic treatment on
EPC response to an AMI, in diabetic patients.
In this study, we tested the hypothesis that diabetes
and pre-diabetes states were associated with reduced cir-
culating EPCs levels in the acute phase of a myocardial
infarction (MI) by comparison with patients with normal
glucose metabolism. We also examined the impact of
previous antidiabetic treatment on the dynamics of EPCs
mobilization in diabetic patients following an AMI.
Methods
Study population and selection
A prospective cohort of 686 consecutive patients hospi-
talized in a single Coronary Care Unit (CCU) due
to myocardial infarction, from 5 January 2009 to 23
September 2011, were screened on admission for inclu-
sion. Screening included an interview, clinical examin-
ation, ECG and laboratory assessment. Patients were
excluded if they were >80 years old, showed clinical or
biochemical evidence of concomitant inflammatory dis-
ease, known auto-immune or malignant diseases, severe
peripheral arterial occlusive disease, deep vein throm-
bosis or pulmonary embolism, atrial fibrillation, recent
trauma or surgery (<1 month), recent major bleeding re-
quiring blood transfusion (<6 months), renal insuffi-
ciency (creatinine > 2.0 mg/dl), anemia (hemoglobin <
8.5 g/dl) or thrombocytopenia (<100 000/L), previous cor-
onary bypass surgery, myocardial infarction within the pre-
ceding 2 months, cardiogenic shock, severe valvular disease
or congenital heart disease, co-morbidities associated with a
life expectancy less than 2 years. A regular use of nonsteroi-
dal anti-inflammatory drugs or anticoagulants, patients with
pacemakers, implantable cardioverter defibrillators or
resynchronization devices, and excessive alcohol consump-
tion or illicit drugs abuse that may influence EPC kinetics
were also exclusion criteria. A total of 100 patients were
prospectively included (65% with ST segment elevation
myocardial infarction – STEMI and 35% with non-ST seg-
ment elevation myocardial infarction - NSTEMI) (Figure 1).
All patients received the standard therapy for the acute
phase of MI that included acetylsalicylic acid (ASA), clo-
pidogrel and low-molecular-weight heparin, according to
usual hospital practice.
Baseline demographic data, cardiovascular risk factors
and previous medications were recorded in all patients.
Smoking status was recorded as ever-smoker (past or
current) or non-smoker.
Blood samples were collected to assess chemistry
(including fasting plasma glucose (FPG) and glycosylated
hemoglobin (HbA1C)), total cholesterol, low-density
lipoprotein-cholesterol (LDL-C), high-density lipopro-
tein-cholesterol (HDL-C), triglycerides, high sensitivity
C-reactive protein (hs-CRP), creatinine, and hematolo-
gical parameters in all patients according to standard
hospital practice.
The study was approved by the local ethics committee
(Approval Number: HUC-23-08). All patients gave written
informed consent and research was conducted according
to the principles expressed in the Declaration of Helsinki.
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Classification of glucose metabolism status
DM and glucose metabolism disorders were defined ac-
cording to the American Diabetes Association (ADA)
criteria [15,16]. All patients without previously known
diabetes underwent an Oral Glucose Tolerance Test
(OGTT) on day 4 or 5 of hospitalization. Therefore,
patients were classified as having diabetes if they have a
FPG ≥126 mg/dl, a 2-h glucose ≥200 mg/dl on OGTT, a
A1c ≥ 6.5% or a random plasma glucose ≥200 mg/dl in
a patient with classic symptoms of hyperglycemia or
hyperglycemic crisis. For patients without diabetes, pre-
diabetes was defined as FPG levels of 100–125 mg/dl
(impaired fasting glucose – IFG), 2-hour OGTT glucose
level of 140–199 mg/dl (impaired glucose tolerance -
IGT) or HbA1c values of 5.7%-6.4%. Patients were clas-
sified as having a normal glucose metabolism (NGM)
if they have FPG < 100 mg/dl, 2-hour OGTT glucose
level < 140 mg/dl and HbA1c <5.7%.
Quantification of circulating EPCs by flow cytometry
For the identification and quantification of EPCs, we
have used a standardized protocol - the modified Inter-
national Society for Hematotherapy and Graft Engineer-
ing (ISHAGE) sequential gating strategy - proposed by
Figure 1 Flow diagram of patient recruitment. AF, atrial fibrillation; AMI, acute myocardial infarction; CABG, coronary artery bypass graft;
Hb, hemoglobin; MI, myocardial infarction; yrs, years old.
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Schmidt-Lucke et al. [17]. Briefly, within the first 24 h of
CCU admission, 1 ml of whole blood was collected from
a forearm vein into EDTA tubes, transported into the
cytometry laboratory and processed within 1 to 2 hours
of collection. Hence, 150 μl of whole blood were incu-
bated with the following combination of anti-human
monoclonal antibodies: 10 μl of anti-CD133 conjugated
with allophycocyanin (APC) (Miltenyi Biotec), 5 μl of
anti-CD45 conjugated with APC-H7 (Becton Dickinson),
10 μl of anti-KDR (also known as type 2 vascular endo-
thelial growth factor receptor - VEGF-R2) conjugated
with phycoerythrin (PE) (Sigma), 10 μl of anti-CD34
conjugated with fluorescein isothiocyanate (FITC) (Becton
Dickinson) and 10 μl of anti-CD184 (also known as
CXCR4) conjugated with PE-Cyanine 5 (PE-Cy5) (BD
Pharmingen) for 30 min at 4°C, in the dark. Red blood
cell lysis was performed using FACS Lysing Solution
(BDBiosciences) diluted 1:10 (vol/vol) in distilled water
and washed with phosphate-buffered-saline (PBS) before
flow cytometry acquisition. Data acquisition was per-
formed with a high-performance flow cytometer, a
BDBioscience FACSCanto II, which can analyze with
high resolution up to eight different fluorescent markers
from a large number of events and we used the flow
cytometry software Infinicyt 1.5 (Cytognos) for the
analysis. According to the used standardized protocol,
human circulating EPCs were identified by a minimal
antigenic profile that includes at least one marker of
stemness/immaturity (CD34 and/or CD133), plus at
least one marker of endothelial commitment (KDR).
CD45 staining was also performed to exclude leucocytes,
as it has been previously demonstrated that only the
fraction of CD45dim cells harbours the “true” circulating
EPCs [18]. CXCR4, the receptor for stromal cell–derived
factor-1 (SDF-1), is a cell surface antigen expressed in
EPCs, which plays a key role in their transendothelial
migration and homing to sites of vascular injury [19].
Therefore, by analyzing the subpopulation of progenitors
coexpressing CXCR4, we could study a functional param-
eter of EPCs. As isotype controls are known to mask rare
cell populations, none were used in this analysis, and base-
line fluorescence was determined using unstained cells
[20]. Because EPCs are extremely rare events in peripheral
blood, additional strategies were applied in order to in-
crease the sensitivity of the method and the accuracy of
our work. These included: automatic compensation for
minimizing fluorescence spillover, exclusion of dead cells,
and use of specific high quality mononuclear antibodies.
The total number of acquired events was increased to at
least 1 million per sample, which is generally not needed
for most other applications of flow cytometry. Circulating
EPCs were measured in triplicate from the same patients,
revealing a very close correlation (r = 0.87, p < 0.0001).
The same trained operator, who was blind to the clinical
status of the patients, performed all the cytometric ana-
lysis throughout the study.
Four different populations of EPCs were quantified: 1)
CD45dimCD133+KDR+ cells; 2) CD45dimCD34+KDR+
cells; 3) CD45dimCD34+CD133+KDR+ triple positive
cells; and 4) the subpopulation of CD45dimCD34+KD
R+CXCR4+ EPCs.
Patients follow up for cardiovascular events
All patients were followed up for 24 months after dis-
charge. The following cardiovascular events were recorded:
cardiovascular death; nonfatal stroke or transient ischemic
attack; re-infarction; unstable angina and re-hospitaliza-
tion for unstable angina or heart failure. We also analyzed
the combined endpoint of cardiovascular death, re-hospi-
talization for ACS and unplanned PCI – Major Adverse
Cardiac Events (MACE). Cardiovascular death was de-
fined as death due to a MI or stroke or documented
sudden cardiac death. For patients experiencing more
than one acute event, only the first event was consid-
ered in the analysis.
Statistical analysis
Statistical analyses were performed using SPSS software
version 20.
Based on previous data, we estimated a 40% reduction
in circulating EPCs of diabetics by comparison with non-
diabetic patients. Therefore, a minimum sample size of
18 patients in each group would provide 90% power to
detect difference in circulating EPCs between diabetic
and nondiabetic patients, using a two-sided hypothesis
test with a significance level (alpha) of 0.05.
Continuous variables were tested for normal distribution
by Kolmogorov–Smirnov test and expressed as mean ±
standard deviation or median ± interquartile range for
parametric and nonparametric data, respectively. Categor-
ical data are expressed as counts and percentages.
For comparison of continuous data unpaired Student
t-tests or ANOVA tests were used when variables were
normally distributed and nonparametric Mann–Whitney
test or Kruskal-Wallis test for variables without a normal
distribution. Categorical variables were compared with
the chi-square test or with Fisher exact test as appropriate.
The relationship between variables was calculated using
Pearson’s or Spearman’s correlation coefficient, whichever
appropriate. Multivariate linear regression analysis was
used to assess the relationship between circulating EPCs
levels and HbA1c, after adjustment for confounding var-
iables. Kaplan-Meier survival analyses were performed
to evaluate time-dependent outcomes. Differences between
pairs of survival curves were tested by the log-rank test.
For all analyses, a 2-sided value of P < 0.05 was considered
statistically significant.
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Results
Characteristics of the study population
There were 38 patients with DM, 13% of them with newly
diagnosed DM. Overall, diabetics had similar age and
cardiovascular risk factors as nondiabetic patients, except
for hypertension that was significantly more frequent in
diabetics (Table 1). Additionally, they tended to have more
frequently previously known CAD and were more often
Table 1 Comparison of clinical characteristics between diabetic and nondiabetic patients
Non-diabetics (N = 62) Type 2 diabetics (N = 38) p value
Age (years)* 59.8 ± 10.3 61.5 ± 11.0 0.300
Male gender (%) 90.3 89.5 0.891
BMI (Kg/m2)* 27.9 ± 4.4 29.2 ± 6.9 0.251
Previous CAD (%) 14.5 31.6 0.075
Previous MI (%) 11.3 18.4 0.319
Type of MI
STEMI vs NSTEMI (%) 66.1/33.9 63.2/36.8 0.762
Cardiovascular risk factors
Hypertension (%) 56.5 84.2 0.004
Smoking habits (%) 61.3 47.4 0.215
Family history (%) 37.1 28.9 0.492
Hyperlipidemia (%) 71.1 82.3 0.189
Physical inactivity (%) 56.5 60.5 0.689
Previous cardiovascular or antidiabetic drugs
Statins (%) 29.0 31.6 0.825
ASA (%) 19.4 42.1 0.021
ACEI (%) 12.9 36.8 0.007
ARB (%) 12.9 31.6 0.038
Beta-blockers (%) 9.7 21.1 0.141
Insulin (%) 0.0 26.3 <0.001
Oral hypoglycemic (%) 0.0 65.8 <0.001
Baseline laboratory
Admission Troponin I (μg/L)§ 0.7 ± 5.8 1.5 ± 3.6 0.798
Peak Troponin I (μg/L)§ 55.4 ± 71.6 56.7 ± 64.7 0.793
HbA1C (%)§ 5.6 ± 0.5 7.1 ± 2.2 <0.001
Admission glycemia (mg/dl)§ 109.0 ± 31.0 206.5 ± 110.8 <0.001
First fasting glycemia (mg/dl)§ 103.0 ± 24.5 156.0 ± 52.5 <0.001
Total cholesterol (mg/dl)* 178.5 ± 59.0 211.7 ± 54.9 0.007
LDL cholesterol (mg/dl)* 113.2 ± 39.6 145.3 ± 44.3 <0.001
HDL cholesterol (mg/dl)§ 40.2 ± 9.5 38.7 ± 12.9 0.164
Triglycerides (mg/dl)§ 138.5 ± 109.5 148.0 ± 88.5 0.801
Uric acid (mg/dl)* 5.6 ± 1.3 6.2 ± 1.4 0.096
Baseline creatinine (mg/dl)§ 0.8 ± 0.3 0.9 ± 0.4 0.123
Baseline hemoglobin (g/dl)* 14.8 ± 1.4 14.4 ± 1.2 0.200
Admission hs-CRP (mg/dl)* 0.9 ± 1.3 1.0 ± 1.4 0.872
LVEF (%)* 52.6 ± 9.6 50.0 ± 11.8 0.104
Hospital length of stay§ 5.4 ± 2.6 5.9 ± 3.0 0.424
ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin II receptor blockers; ASA, acetylsalicylic acid; CAD, coronary artery disease; hs-CRP, high
sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation
myocardial infarction.
*mean ± SD.
§median ± interquartile range.
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medicated with ASA, ACE-inhibitors and ARB as well as
oral hypoglycemic agents and insulin before admission
than nondiabetics. As expected, diabetics had significantly
higher levels of admission glycemia, fasting glycemia and
HbA1c and also presented higher total cholesterol and
LDL-cholesterol than nondiabetics.
There were no significant differences in MI presentation
(STEMI versus NSTEMI), left ventricular function or
renal function between groups (Table 1).
There were no significant differences in the extent of
coronary atherosclerosis, number of stents deployed or
other cath lab parameters between diabetics and nondia-
betics (Table 2).
Reduction of circulating EPCs in diabetic patients
Circulating EPCs levels were expressed for one million
cytometric events (Figure 2). Diabetic patients had circu-
lating numbers of CD45dimCD34+KDR+ cells reduced
by 63% when compared with nondiabetics, with a paral-
lel decrease in the subpopulation CXCR4+ (Table 3,
Figure 3). There was also a significant reduction in
the more immature population of CD45dimCD34+CD
133+KDR+ EPCs to around half the levels of nondia-
betics, and numbers of its precursors CD45dimCD13
3+KDR+ in peripheral circulation were also significantly
decreased. The subpopulation coexpressing the homing
marker CXCR4 (CD45dimCD133+KDR+CXCR4+) was
also significantly reduced in diabetics (Table 3).
Circulating EPCs levels across the different disorders of
glucose metabolism
Upon OGTT, 24 of the nondiabetic patients had pre-
diabetes (29.2% with impaired fasting glucose - IFG,
58.3% with impaired glucose tolerance – IGT and 12.5%
with both disorders of glucose metabolism).
Circulating CD45dimCD34+KDR+ EPCs decreased as
a continuum from NGM to DM, as there was a
reduction of approximately 40% in patients with pre-
diabetes as compared with NGM patients (p = 0.018)
and there was an additional reduction of these EPCs of
about 40% (p = 0.042) when diabetics were compared with
patients with pre-diabetes (Table 4). Nonetheless, the popu-
lation of more immature progenitor cells (CD45dimCD133
+KDR+) and the subpopulations coexpressing the CXCR4
marker (CD45dimCD34+KDR+CXCR4+ and CD45dimCD
133+KDR+CXCR4+) were not significantly reduced in pre-
diabetic patients by comparison with NGM patients (5.4 ±
2.4 vs 3.9 ± 2.8, p = 0.314; 1.8 ± 0.9 vs 1.3 ± 1.2, p = 0.175;
and 3.5 ± 2.1 vs 3.2 ± 1.3, p = 0.290, respectively), whereas a
significant reduction was apparent from pre-diabetic to
diabetic patients on these cells levels (p = 0.022; p = 0.045
and p = 0.015, respectively) (Table 4).
Circulating EPCs numbers according to previous
antidiabetic treatment
Regarding the antidiabetic strategy before admission,
there were 53% of diabetic patients on oral hypoglycemic
drugs, 26% insulin-treated diabetics, and 21% of patients
who were not taking any antidiabetic drug (because they
were on diet-only therapy or new onset DM was diag-
nosed during hospitalization). As expected, diabetes dur-
ation was significantly longer in insulin-treated patients
(13.5 ± 9.8 years versus 6.8 ± 5.0 in patients on oral
hypoglycemic drugs versus 1.7 ± 1.2 in diabetics not re-
ceiving any antidiabetic drug, p = 0.001). Insulin-treated
DM (ITDM) patients and diabetics not previously treated
with antidiabetic drugs presented a worse glycemic control
as compared with patients on oral hypoglycemic drugs
(Figure 4).
Numbers of CD45dimCD34+KDR+ EPCs were signifi-
cantly reduced in diabetic patients previously treated
with oral antidiabetic drugs and in diabetics not taking
any hypoglycemic drug when compared with nondia-
betic patients (Figure 5, A). However, despite the worse
Table 2 Comparison of catheterization lab data between diabetics and nondiabetics
Non-diabetics (N = 62) Type 2 diabetics (N = 38) p value
Catheterization during hospitalization (%) 94.7 96.8 0.614
Normal coronaries (%) 5.0 0.0 0.289
1-vessel disease (%) 41.7 41.7 1.000
2-vessel disease (%) 26.7 30.6 0.682
3-vessel disease (%) 26.7 27.8 0.906
Left main disease (%) 6.7 5.7 0.854
LAD disease (%) 69.5 80.6 0.235
PCI before EPCs evaluation (%) 72.6 68.4 0.656
Complete revascularization before EPCs evaluation (%) 44.9 45.3 0.912
Number of stents deployed before EPCs evaluation 1.6 ± 1.1 1.8 ± 1.2 0.649
LAD; left anterior descending, PCI; percutaneous coronary intervention.
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glycemic control of diabetics on chronic insulin, their
CD45dimCD34+KDR+ EPCs levels were not signifi-
cantly reduced compared to that of nondiabetic patients
(p = 0.160) (Figure 5-A). Regarding the subpopulation
of CD45dimCD34+KDR+ cells also expressing the hom-
ing marker CXCR4+, all diabetes treatment categories
presented significantly decreased circulating levels by
comparison with nondiabetic patients (Figure 5-B). Cir-
culating CD45dimCD133+KDR+ cell levels showed a
progressive decline from nondiabetics, untreated DM,
DM on oral hypoglycemic drugs and finally, ITDM, with
patients receiving insulin and patients on oral hypo-
glycemic drugs presenting significantly lower levels
as compared with nondiabetics (p = 0.002 and p = 0.004,
Figure 2 Representative flow cytometry quantification of CD45low/CD34+/KDR+ EPCs in a a nondiabetic patient with STEMI. (A) The
cluster of CD34+ cells (red points) was analyzed using FITC-labeled antibodies against CD34 vs. SSC. B) CD45dim subset analysis was conducted
using APC-H7-labeled antibodies against CD45 vs SSC. At this step, events forming a cluster of characteristic low SSC and low CD45 fluorescence
(SSClowCD45dim cells) expressed CD34+CD45dim cells (light blue events). C) The events fulfilling previous criteria were then displayed on a
forward light scatter (FSC) vs. SSC dot plot to confirm that the selected cells fall into the lymphocyte region. D) Finally, CD45dimCD34+KDR+
endothelial progenitor cells (pink cells) are deducted in the dot plot of PE-labeled antibodies against KDR vs CD34.
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respectively) (Figure 5-C). Circulating levels of the CD4
5dimCD133+KDR+CXCR4+ subpopulation were also
significantly lower in all diabetic treatment categories
than in nondiabetic patients (Figure 5-D).
Impact of glycemic control on EPCs levels
There were significant negative correlations between
levels of circulating CD45dimCD34+KDR+ (Figure 6, A),
CD45dimCD133+KDR+ progenitors (Figure 6, C), their
CXCR4+ subpopulations (Figure 6, B and D) and HbA1c.
CD45dimCD34+KDR+EPCs and their subpopulation CD45
dimCD34+KDR+CXCR4+ were also inversely correlated with
fasting glycemia (r = − 0.371, p < 0.001 and r = − 0.213,
p = 0.046, respectively). Nonetheless, EPCs levels were
not correlated with DM duration. Levels of circulating
CD45dimCD34+KDR+ and CD45dimCD133+KDR+ pro-
genitors were also negatively correlated with age (r =− 0.285,
p = 0.007 and r =− 0.343, p = 0.001, respectively).
Remarkably, correlations with HbA1c remain signifi-
cant even after adjustment for age, gender, hypertension,
LDL-cholesterol, family history of CAD, smoking habits
and physical inactivity (Table 5).
Prognostic impact of EPCs
Clinical outcomes during the 24 months follow-up
period are represented in Table 6.
There were no significant differences in re-infarction,
nonfatal stroke/transient ischemic attack or cardiovascular
Table 3 Comparison of circulating EPCs levels between diabetics and nondiabetics
Non-diabetics (n = 62) Type 2 diabetics (n = 38) p value
Time from PCI to blood sampling (hours) 13.8 ± 14.7 11.6 ± 11.7 0.649
CD34+ cells/106 WBC 228.8 ± 136.7 197.0 ± 115.2 0.098
CD133+/106 WBC 54.4 ± 35.7 36.0 ± 18.0 0.020
CD45dimCD34+KDR+ cells/106 WBC 6.2 ± 3.0 2.3 ± 0.9 <0.001
CD45dimCD34+KDR+CXCR4+ cells/106 WBC 1.8 ± 1.1 0.8 ± 0.7 <0.001
CD45dimCD34+CD133+KDR+ cells/106 WBC 2.1 ± 1.1 1.0 ± 0.8 <0.001
CD133+KDR+/106 WBC 4.6 ± 2.9 3.1 ± 1.6 <0.001
CD133+KDR+CXCR4+/106 WBC 3.5 ± 1.9 2.0 ± 1.2 <0.001
PCI, percutaneous coronary intervention; WBC, white blood cells.
Figure 3 Comparison of circulating EPCs levels between diabetics and nondiabetics. Bars represent median and error bars interquartile
range of circulating EPCs numbers quantified by flow cytometry. Mann Whitney U test was used for the comparison between diabetic and
nondiabetic EPCs levels.
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mortality rates between groups. However, the occurrence
of unstable angina, the composite endpoints MACE and
re-hospitalization for unstable angina or heart failure were
significantly higher in diabetics, with the following odds
ratios 6.89 (95% CI, 1.35-35.19), 4.23 (95% CI 1.43-12.53)
and 4.82 (95% CI 1.52-15.30), respectively.
Regarding baseline circulating EPCs levels, patients with
unstable angina, unplanned PCI or MACE during follow-
up presented significantly lower levels of CD45dimCD3
4+KDR+ and CD45dimCD133+KDR+ EPCs. Levels of
the CD45dimCD133+KDR+CXCR4+ EPCs subpopulation
were also significantly reduced, at baseline, in patients
who underwent unstable angina or MACE during the
2-year follow-up period (Figure 7). Additionally, the
Kaplan–Meier survival curves for freedom from MACE
according to EPCs levels showed a significantly lower
event-free survival rate in patients with lower EPCs levels
in the early phases of AMI (log-rank test, p = 0.023 for
CD45dimCD34+KDR+ EPCs and log-rank test, p = 0.004
for CD45dimCD133+KDR+ cells) (Figure 8).
Discussion
There were four major findings in the present study. First,
we confirmed that, in the acute phase of a MI, diabetic pa-
tients present dramatically reduced levels of circulating
EPCs by comparison with nondiabetics. Second, this study
showed for the first time that even pre-diabetes reduces
EPCs response to an AMI, since EPCs levels were signifi-
cantly reduced in pre-diabetics and further reduced in
diabetics as compared with patients with NGM. Third,
Table 4 Comparison of circulating EPCs levels between the different glucose metabolism status
NGM (n = 38) Pre-diabetes (n = 24) Diabetes (n = 38) p value
CD34+ cells/106 WBC 417.3 ± 266.9 225.4 ± 97.5 176.5 ± 148.8 0.006
CD133+/106 WBC 41.5 ± 23.7 34.1 ± 21.2 34.4 ± 19.2 0.101
CD45dimCD34+KDR+ cells/106 WBC 7.0 ± 3.5 4.3 ± 2.7 2.4 ± 1.2 <0.001
CD45dimCD34+KDR+CXCR4+ cells/106 WBC 1.8 ± 0.9 1.3 ± 1.2 0.8 ± 0.7 0.002
CD45dimCD34+CD133+KDR+ cells/106 WBC 1.7 ± 1.0 1.3 ± 1.1 0.7 ± 0.6 0.001
CD133+KDR+/106 WBC 5.4 ± 2.4 3.9 ± 2.8 3.0 ± 1.9 0.002
CD133+KDR+CXCR4+/106 WBC 3.5 ± 2.1 3.2 ± 1.3 2.0 ± 1.4 0.002
NGM, normal glucose metabolism; WBC, white blood cells.
Figure 4 Glycosylated hemoglobin levels according to chronic antidiabetic treatment. Box plots represent the interquartile range of values,
the horizontal lines show the median, and whiskers represent the maximum and minimum values. In order to find between which antiadiabetic
treatment categories there were significant differences, we compared two by two groups using the Mann Whitney U test.
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previous chronic insulin therapy (but not oral antidiabetic
drugs) seems to attenuate the deficit in circulating EPCs
seen in diabetic patients with an AMI. Finally, we have
demonstrated that the degree of glycemic control is an im-
portant determinant of circulating EPCs numbers in the
setting of an AMI.
An AMI is a recognized pathological stimulus for
EPCs mobilization. In fact, patients with AMI present
significantly increased numbers of circulating EPCs as
compared with control subjects or with patients with
stable angina [8]. It has been shown that circulating
EPCs increase immediately after the onset of an AMI,
with a subsequent peak at day 5 and a rapid decline
thereafter, normalizing within 2 months [21,22]. Circu-
lating EPCs constitute a key endogenous repair mechan-
ism to counteract ongoing endothelial cell injury, replace
dysfunctional endothelium, and enhance tissue repair after
ischemic vascular injury [23]. Of note, depletion of
circulating EPCs pool and impaired migratory activity of
these progenitor cells have been shown to be predictive of
future adverse cardiovascular events [24,25]. In accord-
ance with these previous studies, our work showed that
freedom from MACE following an AMI was significantly
poorer in patients with lower baseline EPCs levels.
It has been extensively demonstrated that patients
with DM have a profound reduction of EPCs levels in
peripheral blood, which has been correlated with the
high cardiovascular morbidity and mortality associated
with diabetes [10,26]. Additionally, reduced EPCs num-
bers have been independently associated with impaired
myocardial function in diabetic patients [27]. Fadini
et al. have demonstrated in diabetic animals, a deficient
EPCs mobilization and impaired compensatory angio-
genesis after hindlimb ischaemia-reperfusion injury [28].
However, in the clinical setting of AMI, and despite the
important vascular protective role of EPCs, to date, only
Figure 5 Comparison of circulating EPCs levels between nondiabetic patients and diabetics under different antidiabetic treatments.
(A) Circulating numbers of CD45dimCD34+KDR+ cells; (B) Circulating numbers of CD45dimCD34+KDR+CXCR4+ cells; (C) Circulating numbers of
CD45dimCD133+KDR+ cells and (D) Circulating numbers of CD45dimCD133+KDR+CXCR4+ cells. Bars represent median and error bars interquartile
range of circulating EPCs numbers quantified by flow cytometry. We compared two by two groups using the Mann Whitney U test, to evaluate
between which antiadiabetic treatment category there were significant differences.
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three clinical studies have studied the dynamics of EPCs
mobilization in diabetic patients [21,22,29]. In those
studies, circulating EPCs levels were decreased in dia-
betics [21,22] (or hyperglycemic patients, in the Marfella
et al. study) [29] compared with non-diabetic patients
immediately after the onset of AMI (day 1). Moreover, it
has been demonstrated that the peak level of circulating
EPCs was delayed in diabetic patients compared with
that of nondiabetic patients (from day 5 in nondiabetic
patients to day 7 in diabetic patients) [21,22]. Consistent
with these previous studies, the present work confirmed
that circulating EPCs levels were strikingly reduced in the
early phases of an AMI in diabetic patients as compared
with nondiabetic patients. Of note, this importantly reduc-
tion in EPCs levels seen in diabetic patients does not seem
justified by differences in myocardial ischemia or different
coronary revascularization procedures between groups, as
values of troponin I (a highly specific marker of myocar-
dial injury) and coronary revascularization were similar in
diabetic and nondiabetic patients.
It has become evident that circulating EPCs numbers
were inversely correlated to the severity of CAD [30,31].
However, in the present study the huge difference in
EPCs levels between AMI diabetics and nondiabetics
cannot be explained by differences in CAD severity,
since there were no significant differences in the exten-
sion of coronary stenosis between both groups.
A large body of evidence links classical cardiovascular
risk factors, such as hypertension, with reduction in cir-
culating EPCs [32]. In this study population, diabetics
presented a significantly higher prevalence of hypertension
that could exacerbate the difference in EPCs levels as
compared with nondiabetics. However, diabetics were also
more frequently treated with drugs that recognizably
Figure 6 Relationship between levels of circulating EPCs and HbA1c. Scatter plots showing significant negative relationship relationship
(Pearson correlation) between HbA1c and circulating levels of: A) CD45dimCD34+KDR+ cells; B) CD45dimCD34+KDR+CXCR4+ cells; C) CD133+KDR+
cells; D) CD133+KDR+CXCR4+ cells.
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increase circulating EPCs numbers, such as ACE-
inhibitors and ARBs, what would counterbalance the
possible reduction on EPCs numbers due to the higher
prevalence of hypertension [14].
EPCs can be identified on the basis of the expression
of surface markers, by flow cytometry, a method consid-
ered the gold standard for the quantification of these
cells in peripheral blood [33]. Of note, there are no
unique or specific surface antigen that can be used to
identify circulating EPCs. Therefore, FACS protocols
must use the combination of various membrane markers
for EPCs quantification. In the present work, we used a
standardized polychromatic FACS protocol based upon
the detection of CD34 (an adhesion molecule expressed
mainly on haematopoietic stem cells) [34], CD133/AC
133 (a surface marker expressed in an immature subset
of EPCs, which share more characteristics of stem/pro-
genitor cells) [35], KDR/VEGF-R2 (a typical endothelial
marker) [36], CXCR4/CD184 (a homing marker) [19]
and CD45dim (critical to exclude myeloid cells and be-
cause it has been previously demonstrated that only the
fraction of CD45dim cells harbors the “true” circulating
EPCs) [17,18]. Importantly, there are no studies in the
literature that have attempted to quantify, at the same
time, both CD45dimCD34+KDR+EPCs and the more
immature population of CD45dimCD133+KDR+ pro-
genitors in patients with AMI. Thus, until now there has
been no data available on the relation between these 2
populations in diabetics with an AMI, which would be
important to elucidate the mechanisms underlying their
impaired response. In this study, we showed for the first
time that, not only CD45dimCD34+KDR+ but also 2
the more immature precursors CD45dimCD34+CD13
3+KDR+ and CD45dimCD133+KDR+ were significantly
reduced in diabetic AMI patients by comparison with
nondiabetics. Based on these results, it is tempting to
speculate that EPCs reduction in diabetes was due, at
least in part, to impaired bone marrow mobilization.
Because, if the reduction in EPCs levels was motivated
by a decrease in survival alone it would be expected to
have reduced levels of CD45dimCD34+KDR+ but in-
creased, or at least normal, levels of the more immature
population of CD45dimCD133+KDR+ cells, due to posi-
tive feedback stimulation of bone marrow recruitment.
What we verified here was that the reduction in the
more mature EPCs population was not accompanied by
the expected up regulation of the more immature ones.
In fact, despite the reduction in CD45dimCD34+KDR+
Table 5 Multivariate regression analysis assessing the correlation between HbA1c and circulating progenitor cells
levels, after adjustment for other cardiovascular risk factors than diabetes
Variable CD45dimCD34+KDR+ levels CD45dimCD34+KDR+CXCR4+ levels CD133+KDR+ levels CD133+KDR+CXCR4+ levels
Standard
coefficient (ß)
p Standard
coefficient (ß)
p Standard
coefficient (ß)
p Standard
coefficient (ß)
p
HbA1c −0.308 0.019 −0.260 0.031 −0.342 0.009 −0.416 0.001
Age −0.188 0.217 −0.107 0.482 −0.254 0.090 −0.052 0.720
Gender 0.208 0.067 0.207 0.119 0.044 0.740 0.158 0.233
Hypertension −0.071 0.597 −0.075 0.579 0.025 0.855 −0.015 0.905
LDL-cholesterol −0.057 0.683 −0.047 0.727 −0.176 0.202 −0.148 0.267
Family history of CAD −0.129 0.361 −0.170 0.202 0.081 0.560 0.078 0.563
Smoking habits 0.003 0.985 −0.204 0.188 −0.086 0.563 −0.133 0.369
Physical inactivity −0.203 0.139 −0.080 0.556 −0.057 0.657 −0.167 0.180
Adjusted R2 0.264 … 0.256 … 0.246 … 0.247 …
Significance (ANOVA) … 0.032 … 0.040 … 0.046 … 0.033
CAD, coronary artery disease; HbA1c, hemoglobin A1c; LDL, low density lipoprotein.
Table 6 Comparison of clinical outcomes after AMI between diabetics and nondiabetics
Nondiabetics (N = 62) Diabetics (N = 38) Odds ratio P value
Cardiovascular mortality (%) 1.6 7.9 5.2 0.120
Stroke or TIA (%) 0 5.4 - 0.064
Re-infarction (%) 3.3 0 - 0.266
Unstable Angina (%) 3.3 18.9 6.9 0.009
Re-hospitalization for UA or HF (%) 8.1 29.7 4.8 0.005
MACE (%) 9.8 31.6 4.2 0.006
AMI, acute myocardial infarction; HF, heart failure; MACE, Major Adverse Cardiac Events; TIA, transient ischemic accident; UA, unstable angina.
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levels, CD45dimCD133+KDR+ and CD45dimCD34+CD
133+KDR+ precursors were also reduced, pointing to
impairment in recruitment mechanisms.
Besides the reduction in EPCs counts, we found that
the fraction of EPCs coexpressing the homing receptor
CXCR4 were also significantly reduced in diabetic AMI
patients what may represent an impaired homing cap-
acity of these cells to sites of vascular damage. In fact,
CXCR4, the only known receptor for SDF-1, has been
reported to play an important role in EPCs homing [19].
Moreover, CXCR4/SDF-1 interaction influences prolifer-
ation and mobilization of EPCs from the bone marrow
[37]. Since functional study of EPCs, in large popula-
tions, with in vitro assays is prohibitively expensive and
time consuming, the analysis by flow cytometry of EPCs
coexpressing CXCR4 may provide a promising alterna-
tive parameter to assess EPCs function. This is the first
study to show a reduction in numbers of EPCs coexpres-
sing CXCR4 in diabetic patients with AMI compared
with AMI nondiabetics. It is probable that this down
regulation in CXCR4+ cells denotes a homing impair-
ment, which in addition to the markedly reduction in
circulating EPCs levels may contribute to the worsened
outcome post-AMI observed in diabetics.
Pre-diabetes is a general term that refers to an inter-
mediate stage between NGM and overt DM, including
IFG and IGT. These disorders of glucose metabolism
confer an increased risk for developing both DM and
cardiovascular events [13,15,38]. In the present study
we have found that CD45dimCD34+KDR+ EPCs were
significantly lower in pre-diabetic patients and further
reduced in those with DM, as compared with individuals
with NGM, suggesting that the reduction in the more
mature EPCs population follows the continuum of DM
development. These findings suggest that circulating
EPCs reduction is an early event in the natural history of
DM, what is in accordance to a previous work of Fadini
et al. [39]. That study has shown, in individuals from a
metabolic outpatient clinic, that circulating CD34+KDR+
cells present a progressive decline from NGM, to predia-
betics and diabetic patients and that both fasting and post-
challenge glucose were inversely related to circulating
CD34+KDR+ EPCs levels [39]. Our work further extends
these findings by the quantification of more immature
EPCs populations and the study of homing function by
the analysis of CXCR4+ subpopulations. Interestingly, we
verified that CD45dimCD133+KDR+ EPCs and both sub-
populations of CXCR4+ EPCs (CD45dimCD34+KDR+CX
CR4+ and CD45dimCD133+KDR+CXCR4+ cells) were
not significantly reduced in pre-diabetic AMI patients,
compared to patients with NGM. One possible explanation
for this divergent influence on different EPCs populations
is that pre-diabetes reduces EPCs survival (with subsequent
reduction CD45dimCD34+KDR+ EPCs levels) but, does
not impair neither bone marrow recruitment of EPCs
(leading to no differences in levels of CD45dimCD133
+KDR+ EPCs) nor homing processes (explaining the nor-
mal proportion of EPCs coexpressing CXCR4).
Previous in vitro and several animal studies have dem-
onstrated that insulin therapy has a protective role over
Figure 7 Comparison of baseline EPCs levels between patients with or without cardiovascular events during the 2-year follow-up
period. Bars represent median and error bars interquartile range of circulating EPCs numbers, quantified by flow cytometry within the first 24 h
of admission. We compared EPCs levels between patients with versus without MACE (left panel) and between patients with versus without
unstable angina (right panel), using the Mann Whitney U test.
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EPCs function [40-42]. More recently, Marfella et al.
have demonstrated, in hyperglycemic patients with AMI,
that EPCs levels increased after insulin infusion for in-
tensive glycemic control [29]. Regarding oral antidiabetic
drugs, several clinical studies have shown that PPAR-γ
agonists, such as rosiglitazone and pioglitazone and also
DPP-4 inhibitor sitagliptin increase EPCs levels and im-
prove their function in diabetic patients [43-45]. How-
ever, little is known about the molecular mechanisms
that regulate the beneficial effects of all these antidia-
betic drugs over EPCs.
Importantly, evidence demonstrates that the degree of
hyperglycemic control in diabetic patients is closely re-
lated to circulating EPCs levels [46,47]. However, despite
the obvious interest to know the impact of chronic anti-
diabetic therapy on EPCs response of diabetic patients
to an AMI, until now there have been no studies in
the literature addressing this subject. Therefore, in the
present work we have studied this issue and verified that,
despite the longer DM duration and the worse glycemic
control, insulin treated patients presented levels of
CD45dimCD34+KDR+ EPCs that tended to approach
that of nondiabetics. Conversely, CD45dimCD133+KD
R+ EPCs and subpopulations coexpressing the CXCR4
receptor were not ameliorated by chronic insulin ther-
apy, presenting the lowest levels in patients previously
under insulin. Regarding oral antidiabetic drugs we were
surprised to find no beneficial effect on EPCs levels,
since these results differ from some published studies
[43-45]. Notably, in accordance with the literature our
results further demonstrated that levels of both CD45
dimCD34+KDR+ and CD45dimCD133+KDR+ EPCs and
even their subpopulations coexpressing the CXCR4 sur-
face marker were inversely correlated with HbA1c,
underscoring the importance of the glycemic control for
EPCs response to an AMI. Taken together, these results
suggest that insulin, but not oral antidiabetic drugs, may
increase survival of circulating EPCs (denoted by the
trend to the normalization of CD45dimCD34+KDR+
levels). So, it is tempting to speculate that the favorable
clinical outcomes associated with glycemic control
during AMI may be partly dependent on stimulation
of EPCs-mediated neovascularization in the ischemic
myocardium. However, even chronic insulin treatment
Figure 8 Kaplan-Meier MACE-free survival curves following an AMI, according to circulating EPCs levels presented in the acute phase.
A) Comparison of MACE-free survival curves between patients with levels of CD45dimCD34+KDR+ cells above (red line) or below (blue line) the
median. B) Comparison of MACE-free survival curves between patients with levels of CD133+KDR+ cells above (red line) or below (blue line) the
median level. The p value was determined by log-rank test.
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seemed unable to correct the characteristic dysfunction
of diabetics EPCs (here illustrated by the decrease in
CD45dimCD133+KDR+ EPCs, which may represent an
impairment in mobilization from bone marrow, and re-
duction in CXCR4+ subpopulations, denoting a possible
homing dysfunction). Yet, since patients under insulin
therapy had the highest HBA1c levels, it is still unknown
if with a better glycemic control chronic insulin therapy
could reverse EPCs dysfunction of diabetic patients
and completely normalize their response to an AMI.
Altogether, our results suggest that chronic hyperglycemia
and not diabetes per se, is the responsible for impaired
EPCs response of diabetic patients to myocardial ischemia.
Limitations
The limitations of our study should be acknowledged: 1)
the widespread interlaboratory variations in FACS meth-
odology used to quantify circulating EPCs is still a prob-
lem. In this study we used a standardized protocol,
which has demonstrated a high accuracy in the detection
of different EPCs subpopulations with angiogenic prop-
erties and enable us to study the differentiation and
commitment of these cells, from early precursors to
more mature circulating EPCs [17,48]. However, we
recognize that further standardization of EPCs defini-
tions and FACS protocols would be important to better
compare results between different groups; 2) the long
list of exclusion criteria limited the enrollment of higher
number of AMI patients in this study, resulting in a rela-
tively small number of patients in each antidiabetic
treatment group. Therefore, the data regarding the com-
parison of EPCs levels between the different antidiabetic
treatment categories should be interpreted with caution
because of the risk of error type II and further studies to
explore how insulin therapy may interact and affect dia-
betic EPC numbers and function in patients with AMI,
are obviously warranted; 3) since investigation of the
molecular mechanisms regulating circulating EPCs levels
in AMI diabetic patients was not under the scope of this
study, the signaling pathways underlying the observed
reduction in EPCs levels during the early phases of AMI
in diabetic as compared to nondiabetic patients are
unknown”.
Conclusions
In summary, our data demonstrates that there is a pro-
gressive decrease in EPCs response to an AMI, according
to the glycemic continuum, from NGM to pre-diabetes
and finally DM, and that the exhaustion of the EPCs pool
is influenced by the degree of glycemic control. Further-
more, it seems conceivable to use therapeutic interven-
tions, such as insulin, to try to reverse the impaired
response to an AMI of diabetics and possibly improve the
dismal prognosis of these patients.
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Based on the overall data of this thesis, several conclusions can be drawn:
• The in vivo study confirms that diabetic patients have strikingly reduced levels of circulating 
EPCs in the early phases of an AMI as compared to their non-diabetic counterparts. It further 
extends our knowledge on EPCs by demonstrating that the fraction of EPCs coexpressing the 
homing receptor CXCR-4 is also significantly reduced in diabetic patients, suggesting an impaired 
homing capacity to the sites of needed neovascularization in the ischemic tissue and damaged 
endothelium, in DM. Additionally, by comparing for first time, EPCs from diabetic patients with 
those of matched non-diabetic patients with an AMI, the in vitro study shows that DM has a 
significant negative impact on several functional parameters of EPCs, namely on their prolif-
eration, expression of hallmark surface markers and homing capacity.      
 
In summary, DM dramatically impairs the response of endogenous EPCs to an AMI, by affecting 
both numbers and function of circulating EPCs.
• The mechanisms that regulate EPCs release and maintenance in peripheral blood, as well as the 
mechanisms underlying the reduction of circulating EPCs numbers and their functional impair-
ment in diabetic patients, remain to be clearly elucidated. This thesis has helped to clarify the 
mechanisms involved in EPCs impairment in DM. Until now there were no data available on the 
relation between different populations of EPCs according to their maturation state, in diabetic 
patients. This relation is of obvious interest since it can help to elucidate the mechanisms 
underlying the impaired response of EPCs to an AMI in diabetic patients. If the mechanism re-
sponsible for the reduction in circulating EPCs levels was an impaired mobilization from bone 
marrow, it would be expected to have a decrease, not only in the more mature EPCs but also in 
the more immature ones. However, if the cause of this reduction was a reduced survival in the 
peripheral circulation, it would be expected to have reduced levels of the more mature EPCs but 
normal, or even increased, levels of the more immature populations, due to positive feedback 
stimulation of bone marrow recruitment. The simultaneous quantification of both circulating 
CD45dimCD34+KDR+ EPCs and the more immature populations of CD45dimCD34+CD133+KDR 
and CD45dimCD133+KDR+ progenitors shows that the reduction in the more mature EPCs 
population was not accompanied by the expected compensatory upregulation of the more 
immature ones, suggesting that the reduced response of diabetic EPCs to an AMI is due to 
impaired bone marrow mobilization and not simply a result of decreased survival.    
 
Taken together, the results of this translational research suggest as underlying mechanisms of 
EPCs impairment in diabetes: a reduction of EPCs mobilization from the bone marrow, a de-
creased proliferative capacity, and an impaired homing ability, but not a decrease in survival.
• This thesis first describes that even pre-diabetes negatively influence the response of EPCs 
to an AMI. The present results demonstrate that in the acute phase of a MI, circulating EPCs 
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numbers were significantly reduced in pre-diabetic patients and further reduced in diabetic 
patients as compared with patients with NGM. Nevertheless, the levels of the more immature 
EPCs and the proportion of EPCs coexpressing the homing marker CXCR-4 were not reduced 
in pre-diabetic patients, suggesting that pre-diabetes negatively impact on EPCs survival, 
but not on their homing processes or bone marrow recruitment.      
 
Therefore, it is now evident that the impaired response of EPCs to an AMI is an early event in 
the natural history of DM, being already compromised in pre-diabetic patients. The reduction 
in circulating EPCs numbers is gradual, accompanying the glycemic continuum.
• Another important conclusion of this dissertation is that the degree of glycemic control is an 
important determinant of circulating EPCs levels in AMI patients. In the present work, numbers 
of all EPCs populations are negatively correlated with glycosylated hemoglobin, reinforcing 
the importance of the glycemic control to try to improve EPCs-mediated neovascularization in 
diabetic patients with an AMI.
• The finding that experimental hyperglycemic-like conditions induce dysfunction in EPCs from 
non-diabetic AMI patients in vitro, combined with the observation of an inverse correla-
tion between glycemic levels and circulating EPCs levels in vivo, support the hypothesis that 
chronic hyperglycemia per se is sufficient to jeopardize the endogenous response of EPCs to 
an AMI. 
• The present research indicates that chronic insulin therapy might improve EPCs response to 
myocardial ischemia in diabetes, probably through a mechanism beyond glycemic control. In 
fact, despite the longer DM duration and the worse glycemic control, insulin-treated diabetic 
patients tend to present similar circulating levels of the more mature CD45dimCD34+KDR+ EPCs 
to those of non-diabetic patients in the acute phase of an MI, suggesting that chronic insulin 
therapy attenuates the expected deficit in circulating EPCs of diabetic patients. Since levels of 
the more immature EPCs populations and the fraction of EPCs coexpressing the homing marker 
CXCR-4 appear to be unchanged by insulin therapy, an increase in survival of the more mature 
population of EPCs seems to be the most likely mechanism involved in the potential benefit of 
insulin therapy over EPCs in vivo. However, it is still unknown whether, under better glycemic 
control, chronic insulin therapy could completely reverse EPCs dysfunction of diabetic patients 
and normalize their response to an AMI.
• Through the combination of both in vitro and in vivo studies, this thesis provides evidence that 
statin therapy remarkably increases the levels of circulating EPCs and significantly improves 
their function, in the clinical setting of an AMI. Moreover, it indicates that this stimulation 
of EPCs by statins may be, at least in part, mediated through their well-known anti-inflam-
matory action. The in vitro exposure of EPCs to statins consistently improve several functional 
parameters of EPCs, such as proliferation, survival and expression of the homing marker, 
CXCR-4. It is worth noting that in our cohort of AMI patients, prior chronic statin therapy 
enhanced EPCs response to myocardial ischemia, even in diabetic patients. Furthermore, 
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despite the profound dysfunction of EPCs associated with diabetes, the in vitro function-
al benefits of statins over EPCs were also verified in cells from diabetic patients.    
In summary, this thesis indicates that statin therapy can correct the functional impairment of 
EPCs from diabetic patients, excluding therefore, the hypothesis of an irreversible “hypergly-
cemic memory” effect of diabetes over EPCs.
• Finally, this work suggests that statin stimulation of the endogenous EPCs response to an AMI 
is dose-dependent. In this research, we compared for the first time the effect of different 
intensities of statin therapy at discharge on the evolution of circulating EPCs levels after an 
AMI, verifying that only the high-intensity statin regimen prevents the expected decrease of 
circulating EPCs levels during the post-MI period. Therefore, it is tempting to speculate that 
high-intensity statin therapy can counteract the expected decline in EPCs levels following an 
AMI, because it is a so strong stimulus for EPCs recruitment, that it parallels the stimulation 
mediated by myocardial ischemia in the acute phase of a MI. In a clinical point of view, these 
findings strongly reinforce the importance to follow the current recommendation, and start 
high-intensity statin therapy early in all patients with AMI.
Taken together the results presented in this thesis may have important clinical implications, since 
they demonstrate that the profound impairment of EPCs associated with DM can be pharmaco-
logically reverted. Therefore, pharmacological strategies to enhance the endogenous response of 
EPCs in diabetic patients with an AMI appear as a realistic goal and can be actively pursued in an 
attempt to improve the worse outcomes of this increasing population. 
This dissertation provides many answers but raises even more questions. In order to elucidate 
the molecular mechanisms underlying the regenerative role of EPCs in vivo and to identify the 
specific targets for appropriate patient-tailored pharmacological modulation, there are still open 
issues that need to be addressed in future research. Do EPCs directly participate in regeneration 
of the damaged endothelium or simply act indirectly through paracrine mechanisms? Endothelial 
dysfunction is known to be associated with increased vascular inflammation. Is inflammation a 
causative player or just a marker of EPCs impairment in DM? It has been recently suggested that 
non-coding RNAs or microRNA (miRNAs) are key players in the pathogenesis of hyperglycemia-
induced vascular damage and that the deregulation of specific miRNAs expression may contribute 
to vascular disease in DM.  Can the pharmacological modulation of specific miRNAs improve 
EPCs-driven repair in diabetic patients? Which are the mechanisms of action, at a molecular 
level, needed to completely normalize the endogenous EPCs pool by pharmacological therapy and 
therefore, ameliorate the native response of EPCs to an AMI in diabetic patients?
Looking towards the future, further investigation on other promising drugs, including new oral 
antidiabetics and antianginal agents, might provide valuable insights for unlocking our innate 
regenerative potential, contributing for the progress of the promising field of regenerative 
pharmacology.

